Physician profile
Robert Lipson
NPI 1942202643
$10,355.50
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,390 · 2020: $3,170 · 2021: $886 · 2022: $1,711 · 2023: $2,188 · 2024: $1,010.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,198.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $3,574.40 | 2019-2024 | |
| Coloplast Corp | $936.49 | 2019-2024 | Speedicath, Titan |
| Valencia Technologies Corporation | $925.58 | 2022-2023 | Ecoin Device Kit |
| Boston Scientific Corporation | $719.17 | 2019-2024 | Spaceoar Vue System - 10ml, Rezum Generator, Ams 700 |
| Abbvie INC. | $534.13 | 2019-2024 | |
| Sumitomo Pharma America, INC. | $513.17 | 2023-2024 | Gemtesa |
| Astellas Pharma US INC | $387.22 | 2019-2023 | Xtandi, Myrbetriq |
| Axonics, INC. | $385.74 | 2022-2024 | Bulkamid, Axonics |
| Teleflex LLC | $242.03 | 2021-2023 | Urolift |
| Janssen Biotech, INC. | $237.40 | 2019-2024 | Erleada |
| Myriad Genetic Laboratories, INC. | $217.10 | 2022-2024 | Prolaris |
| Progenics Pharmaceuticals, INC. | $149.06 | 2023-2024 | Pylarify |
| Olympus America INC. | $148.81 | 2023 | Itind System |
| Neotract INC. | $146.69 | 2019 | |
| Innovation Technologies INC | $134.26 | 2023 | Irrisept |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lipson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.